Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Friedlander

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancerB Thewes, B Meiser, A Taylor, et al.
Gynecologic Oncology|December 3, 2005
Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG studyM L Harrison, P Hoskins, A du Bois, et al.
Clinical Genetics|August 23, 2006
Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort studyK-A Phillips, M A Jenkins, G J Lindeman, et al.
Breast Cancer Research and Treatment|August 19, 2011
Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive familiesS L Harvey, R L Milne, S A McLachlan, et al.
Gynecologic Oncology|November 1, 1988
Ovarian carcinoma: abdominopelvic irradiation following reexplorationH J Solomon, K H Atkinson, J V Coppleson, et al.
The Medical Journal of Australia|May 19, 1997
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapyM Michael, J F Bishop, J A Levi, et al.
Familial Cancer|March 23, 2011
Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancerB E Kiely, M L Friedlander, R L Milne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase InhibitorAngelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2008
Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancerK M Field, M A Jenkins, M L Friedlander, et al.
Familial Cancer|March 13, 2017
Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancerY C Lee, M Bressel, P Grant, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancerB Thewes, B Meiser, A Taylor, et al.
Gynecologic Oncology|December 3, 2005
Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG studyM L Harrison, P Hoskins, A du Bois, et al.
Clinical Genetics|August 23, 2006
Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort studyK-A Phillips, M A Jenkins, G J Lindeman, et al.
Breast Cancer Research and Treatment|August 19, 2011
Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive familiesS L Harvey, R L Milne, S A McLachlan, et al.
Gynecologic Oncology|November 1, 1988
Ovarian carcinoma: abdominopelvic irradiation following reexplorationH J Solomon, K H Atkinson, J V Coppleson, et al.
The Medical Journal of Australia|May 19, 1997
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapyM Michael, J F Bishop, J A Levi, et al.
Familial Cancer|March 23, 2011
Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancerB E Kiely, M L Friedlander, R L Milne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase InhibitorAngelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2008
Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancerK M Field, M A Jenkins, M L Friedlander, et al.
Familial Cancer|March 13, 2017
Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancerY C Lee, M Bressel, P Grant, et al.
Pageof 8